Virax Biolabs Group Ltd (VRAX) concluded trading on Wednesday at a closing price of $4.87, with 67.47 million shares of worth about $328.58 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 407.34% during that period and on August 28, 2024 the price saw a loss of about -0.41%. Currently the company’s common shares owned by public are about 2.57M shares, out of which, 2.07M shares are available for trading.
Stock saw a price change of -23.91% in past 5 days and over the past one month there was a price change of 289.60%. Year-to-date (YTD), VRAX shares are showing a performance of 233.56% which increased to 34.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.60 but also hit the highest price of $9.00 during that period. The average intraday trading volume for Virax Biolabs Group Ltd shares is 4.33 million. The stock is currently trading 87.00% above its 20-day simple moving average (SMA20), while that difference is up 171.87% for SMA50 and it goes to 268.09% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Virax Biolabs Group Ltd (NASDAQ: VRAX) currently have 2.57M outstanding shares and institutions hold larger chunk of about 3.00% of that.
The stock has a current market capitalization of $11.49M and its 3Y-monthly beta is at 1.86. It has posted earnings per share of -$3.12 in the same period. It has Quick Ratio of 25.58 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VRAX, volatility over the week remained 31.34% while standing at 35.25% over the month.
Analysts are in expectations that Virax Biolabs Group Ltd (VRAX) stock would likely to be making an EPS of 0.0 in the current quarter, while forecast for next quarter EPS is 0.0 and it is 0.0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.0 which is 0.0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of nan in the same quarter a year ago.
